EA202190429A1 - Биодоступные пероральные дозированные формы - Google Patents
Биодоступные пероральные дозированные формыInfo
- Publication number
- EA202190429A1 EA202190429A1 EA202190429A EA202190429A EA202190429A1 EA 202190429 A1 EA202190429 A1 EA 202190429A1 EA 202190429 A EA202190429 A EA 202190429A EA 202190429 A EA202190429 A EA 202190429A EA 202190429 A1 EA202190429 A1 EA 202190429A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- dosage forms
- oral dosage
- bioavailable oral
- bioavailable
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862714182P | 2018-08-03 | 2018-08-03 | |
| PCT/US2019/044853 WO2020028778A1 (en) | 2018-08-03 | 2019-08-02 | Bioavailable oral dosage forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190429A1 true EA202190429A1 (ru) | 2021-06-15 |
Family
ID=67766269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190429A EA202190429A1 (ru) | 2018-08-03 | 2019-08-02 | Биодоступные пероральные дозированные формы |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20210205225A1 (https=) |
| EP (1) | EP3829544A1 (https=) |
| JP (1) | JP2021532193A (https=) |
| KR (1) | KR20210041589A (https=) |
| CN (1) | CN112752570A (https=) |
| AR (1) | AR115913A1 (https=) |
| AU (1) | AU2019316036A1 (https=) |
| BR (1) | BR112021001859A2 (https=) |
| CA (1) | CA3107737A1 (https=) |
| CL (1) | CL2021000271A1 (https=) |
| CO (1) | CO2021001979A2 (https=) |
| CR (1) | CR20210093A (https=) |
| EA (1) | EA202190429A1 (https=) |
| EC (1) | ECSP21011795A (https=) |
| IL (1) | IL280471A (https=) |
| MX (1) | MX2021001364A (https=) |
| NI (1) | NI202100006A (https=) |
| PE (1) | PE20211410A1 (https=) |
| PH (1) | PH12021550237A1 (https=) |
| SG (1) | SG11202100984VA (https=) |
| TN (1) | TN2021000021A1 (https=) |
| TW (1) | TW202019414A (https=) |
| WO (1) | WO2020028778A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX373926B (es) | 2009-05-27 | 2020-07-10 | Ptc Therapeutics Inc | Metodos para tratar cancer y estados no neoplasicos. |
| EP3664803A4 (en) | 2017-08-01 | 2021-05-05 | PTC Therapeutics, Inc. | DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS |
| CN112028888B (zh) * | 2020-09-11 | 2021-08-20 | 中国药科大学 | 一种化合物及其制备方法和用途 |
| US20250186437A1 (en) | 2021-12-31 | 2025-06-12 | Ptc Therapeutics, Inc. | Carboline compounds and use thereof |
| US20220151938A1 (en) * | 2022-01-28 | 2022-05-19 | Ptc Therapeutics, Inc. | Tablet for use in treating huntington's disease and method of making the same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050249799A1 (en) | 2004-03-03 | 2005-11-10 | Spherics, Inc. | Polymeric drug delivery system for hydrophobic drugs |
| US7767689B2 (en) | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
| UA92317C2 (ru) | 2004-03-15 | 2010-10-25 | Пи-Ти-Си ТЕРАПЬЮТИКС, ИНК. | Производные карболина, пригодные для ингибирования развития кровеносных сосудов |
| US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| US8076353B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Inhibition of VEGF translation |
| US20100158858A1 (en) | 2007-04-13 | 2010-06-24 | Liangxian Cao | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| DK2200588T3 (da) | 2007-09-25 | 2019-07-01 | Solubest Ltd | Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf |
| WO2009100176A2 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| MX373926B (es) * | 2009-05-27 | 2020-07-10 | Ptc Therapeutics Inc | Metodos para tratar cancer y estados no neoplasicos. |
| US20120202801A1 (en) * | 2009-05-27 | 2012-08-09 | Liangxian Cao | Methods for treating breast cancer |
| WO2017091373A1 (en) * | 2015-11-25 | 2017-06-01 | Patheon Development Services Inc. | Amorphous dispersion granules and oral dosage forms |
-
2019
- 2019-08-02 CA CA3107737A patent/CA3107737A1/en active Pending
- 2019-08-02 TN TNP/2021/000021A patent/TN2021000021A1/en unknown
- 2019-08-02 EP EP19759102.7A patent/EP3829544A1/en not_active Withdrawn
- 2019-08-02 US US17/264,940 patent/US20210205225A1/en not_active Abandoned
- 2019-08-02 KR KR1020217006355A patent/KR20210041589A/ko not_active Ceased
- 2019-08-02 SG SG11202100984VA patent/SG11202100984VA/en unknown
- 2019-08-02 CN CN201980065062.1A patent/CN112752570A/zh active Pending
- 2019-08-02 EA EA202190429A patent/EA202190429A1/ru unknown
- 2019-08-02 MX MX2021001364A patent/MX2021001364A/es unknown
- 2019-08-02 WO PCT/US2019/044853 patent/WO2020028778A1/en not_active Ceased
- 2019-08-02 JP JP2021529250A patent/JP2021532193A/ja active Pending
- 2019-08-02 PE PE2021000157A patent/PE20211410A1/es unknown
- 2019-08-02 AU AU2019316036A patent/AU2019316036A1/en not_active Abandoned
- 2019-08-02 CR CR20210093A patent/CR20210093A/es unknown
- 2019-08-02 BR BR112021001859-0A patent/BR112021001859A2/pt not_active IP Right Cessation
- 2019-08-05 AR ARP190102223A patent/AR115913A1/es not_active Application Discontinuation
- 2019-08-05 TW TW108127793A patent/TW202019414A/zh unknown
-
2021
- 2021-01-28 IL IL280471A patent/IL280471A/en unknown
- 2021-02-01 PH PH12021550237A patent/PH12021550237A1/en unknown
- 2021-02-02 CL CL2021000271A patent/CL2021000271A1/es unknown
- 2021-02-03 NI NI202100006A patent/NI202100006A/es unknown
- 2021-02-18 CO CONC2021/0001979A patent/CO2021001979A2/es unknown
- 2021-02-19 EC ECSENADI202111795A patent/ECSP21011795A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3829544A1 (en) | 2021-06-09 |
| PH12021550237A1 (en) | 2021-10-11 |
| CN112752570A (zh) | 2021-05-04 |
| ECSP21011795A (es) | 2021-03-31 |
| IL280471A (en) | 2021-03-25 |
| KR20210041589A (ko) | 2021-04-15 |
| WO2020028778A1 (en) | 2020-02-06 |
| TN2021000021A1 (en) | 2022-10-03 |
| TW202019414A (zh) | 2020-06-01 |
| AR115913A1 (es) | 2021-03-10 |
| MX2021001364A (es) | 2021-04-13 |
| CL2021000271A1 (es) | 2021-08-20 |
| CA3107737A1 (en) | 2020-02-06 |
| NI202100006A (es) | 2021-05-21 |
| JP2021532193A (ja) | 2021-11-25 |
| CO2021001979A2 (es) | 2021-03-08 |
| US20210205225A1 (en) | 2021-07-08 |
| BR112021001859A2 (pt) | 2021-04-27 |
| CR20210093A (es) | 2021-05-28 |
| AU2019316036A1 (en) | 2021-03-04 |
| SG11202100984VA (en) | 2021-02-25 |
| PE20211410A1 (es) | 2021-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202190429A1 (ru) | Биодоступные пероральные дозированные формы | |
| CY1124548T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου | |
| CY1122792T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου | |
| EA201890654A1 (ru) | Терапевтические композиции для лечения вируса иммунодефицита человека | |
| CY1124532T1 (el) | Δοσολογικα σχηματα για συζευγματα φαρμακου-αντισωματος αντι-tf | |
| EA201792592A1 (ru) | Фармацевтические препараты, содержащие тенофовир и эмтрицитабин | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| EA201992116A1 (ru) | Фармацевтические составы флороглюцинола и триметилфлороглюцинола | |
| EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| EA201792591A1 (ru) | Фармацевтические препараты | |
| EA201990428A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| EA202090542A1 (ru) | Высококонцентрированные лекарственные формы придопидина | |
| EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
| EA201892837A1 (ru) | Физиологически сбалансированные составы для инъекций, включающие фоснетупитант | |
| EA201792401A1 (ru) | Композиции для очищения толстого кишечника и лечения желудочно-кишечных расстройств | |
| EA202090666A1 (ru) | Применение содержащей бензоат композиции для лечения глициновой энцефалопатии | |
| EA201600486A1 (ru) | Фармацевтические композиции, включающие антикоагулянт n-(5-хлорпиридин-2-ил)-2-({4-[этанимидоил(метил)амино]бензоил}амино)-5-метилбензамид | |
| EA201792265A1 (ru) | Способы лечения сердечно-сосудистых заболеваний | |
| EA201691792A1 (ru) | Фармацевтические составы на основе вилдаглиптина | |
| EA201892842A1 (ru) | Фармацевтические композиции, включающие сафинамид | |
| EA201890929A1 (ru) | Низкие дозировки композиций дипиридамола для перорального приема и их использование | |
| BR112019017314A2 (pt) | composições farmacêuticas para terapia de combinação | |
| EA201890477A1 (ru) | Инкапсулированная композиция финголимода | |
| EA201790020A1 (ru) | Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний |